Evidence supporting proteolytic cleavage of insulin-like growth factor binding protein-1 (IGFBP-1) protein in amniotic fluid

Si Eun Lee, Byoung-Don Han, In-Sook Park, Roberto Romero and Bo Hyun Yoon*
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea

Abstract

Objective: The purpose of this study was to determine if: 1) insulin-like growth factor binding protein-1 (IGFBP-1) in amniotic fluid (AF) exhibited proteolytic cleavage in cases of intra-amniotic inflammation; and 2) if the matrix metalloproteinases (MMP-3, MMP-8, MMP-9) in AF are associated with the degradation of IGFBP-1 in AF.

Methods: AF samples (n=20) were obtained from preterm gestations with and without intra-amniotic inflammation. The form of IGFBP-1 in AF was assessed by Western blot analysis and AF MMP-8 concentration was measured by ELISA. Densitometric analysis of Western blot was performed and the fragmented/intact IGFBP-1 ratio was calculated. Proteolysis of AF IGFBP-1 by MMPs was evaluated by incubating AF with exogenous human MMP-3, MMP-8 or MMP-9, and by incubating recombinant human IGFBP-1 in AF with and without inflammation.

Results: 1) IGFBP-1 was present in AF without inflammation as an intact form; however, the fragmented form was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of MMP-8; 4) in-vitro proteolysis experiments showed that AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9; 5) recombinant human IGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation.

Conclusion: The fragmented form of AF IGFBP-1 was significantly increased in AF with intra-amniotic inflammation, and MMPs produced in AF with intra-amniotic inflammation were associated with the proteolytic change of AF IGFBP-1.

Keywords: AF MMP-8; intra-amniotic inflammation; matrix metalloproteinase (MMP); preterm.

Introduction

Intra-amniotic inflammation/infection is a risk factor for impending preterm delivery and adverse pregnancy outcome [2, 11, 14, 28, 31]. Matrix metalloproteinases (MMPs), proteolytic enzymes derived at the site of inflammation, play a central role in the mechanisms responsible for preterm labor or premature rupture of membranes resulting in preterm birth. The amniotic fluid (AF) concentrations of some MMPs (MMP-3, MMP-8, and MMP-9) have been reported to be significantly elevated in the presence of intra-amniotic infection/inflammation [3, 5, 23, 26].

During pregnancy, the insulin-like growth factor binding protein-1 (IGFBP-1) is produced in decidua and exists in high concentration in AF and maternal serum [22, 29]. Insulin-like growth factor binding proteins (IGFBPs) have high affinity to insulin-like growth factors (IGFs) and antagonize the binding of IGFs to their receptors. Indeed, IGFBP-1 is known to be involved in placental development by modulating the action of IGF [8, 10, 12]. Protease-mediated fragmentation of IGFBPs results in release of IGFs from IGF/IGFBP complex and allows free IGFs to bind to and activate IGF receptors [12]. Several studies indicated that MMPs act as IGFBP protease and proteolytic cleavage of IGFBPs by specific MMPs has been reported [7, 8, 10, 17, 20].

The purpose of this study was to investigate if the cleavage of IGFBP-1 by MMPs (MMP-3, MMP-8 and MMP-9) would occur in intra-amniotic inflammation, and if the form of IGFBP-1 would change from intact to fragmented.

Materials and methods

Amniotic fluid

The form of IGFBP-1 was assessed by Western blot analysis in 20 AF samples obtained from preterm gestations. Characteristics of the study cases are described in Table 1. AF samples were collected by transabdominal amniocentesis or at the time of cesarean section and were centrifuged and stored in poly-
Table 1  Characteristics of the study populations.

<table>
<thead>
<tr>
<th></th>
<th>AF without inflammation (n=9)</th>
<th>AF with inflammation (n=11)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>31 (23–34)</td>
<td>31 (25–43)</td>
<td>NS</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>6 (67%)</td>
<td>4 (36%)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amniocentesis (weeks)</td>
<td>32.1 (26.1–36.7)</td>
<td>31.1 (17.9–35.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>delivery (weeks)</td>
<td>39.4 (36.1–41.4)</td>
<td>31.7 (18.1–35.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Indication for</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amniocentesis</td>
<td></td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Preterm labor</td>
<td>6 (67%)</td>
<td>6 (55%)</td>
<td></td>
</tr>
<tr>
<td>Preterm PROM</td>
<td>2 (22%)</td>
<td>4 (36%)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>1 (11%)</td>
<td>1 (9%)</td>
<td></td>
</tr>
</tbody>
</table>

AF = amniotic fluid, NS = not significant, PROM = premature rupture of membranes.

Cases complicated with preeclampsia, intra-uterine fetal growth retardation, major congenital anomalies or multiple pregnancy were not included.

Values expressed as median (range) or number (percentage).

propylene tubes at −70°C until studied. AF was collected after written informed consent was obtained. The Institutional Review Board of Seoul National University approved the collection of biological materials and data from these patients for research purposes. The Seoul National University has a FederalWide Assurance with the Office for Human Research Protections of the Department of Health and Human Services of the United States.

AF inflammation was defined as an elevated AF MMP-8 concentration (>23 ng/ml), as previously reported [27]. MMP-8 concentration was measured with a commercially available enzyme-linked immunosorbent assay (Amersham Pharmacia Biotech, Inc., Bucks, UK). The sensitivity of the test was 0.3 ng/mL. Intra- and inter-assay coefficients of variation were 3.1% and 9.5%, respectively.

Western blot analysis

1–2 μL of human AF was diluted with sodium dodecyl sulfate (SDS)-loading buffer and boiled for 10 min and subjected to SDS–PAGE using 13.5% gels. Proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA) at 30 V for 1 h. Non-specific binding was blocked overnight with a 5% milk protein in 0.1% TBS-T (0.1% [vol/vol] Tween 20 in Tris-buffer saline) at 4°C. After washing with 0.1% TBS-T, the membrane was incubated with 1:1000 dilution of rabbit anti-human IGFBP-1 polyclonal antibody (Upstate, Lake Placid, NY) diluted in the blocker at room temperature for 1.5 h. The membrane was washed and incubated with 1:5000 dilution of alkaline phosphatase-labeled goat anti-rabbit antibody (Zymed Laboratories, San Francisco, CA) diluted in the 0.1% TBS-T at room temperature for 1 h. A BCIP/NBT tablet (Sigma, St Louis, MO) diluted in distilled water was used for development.

AF IGFBP-1 proteolysis by MMPs

The ability of human MMPs to degrade AF IGFBP-1 was evaluated by incubating 2 μL of AF with exogenous human MMP-3, MMP-8 or MMP-9 (6 pmol for each MMP; Calbiochem,

Figure 1  Western blot analysis of amniotic fluid (AF) IGFBP-1 protein; IGFBP-1 was present in AF without inflammation as an intact form of 30 kDa (lane 1–4), however, intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa in AF with inflammation (lane 5–8). Representative cases are shown.
Darmstadt, Germany) in a solution of 50 mM Tris (pH 7.5) containing 150 mM NaCl, 10 mM CaCl₂, and 0.05% Triton (final volume 20 µL). To activate proenzyme, 1 mM p-aminophenylmercuric acetate (APMA) solution (Calbiochem, Darmstadt, Germany) was used. The solution was incubated at 37°C for 12–24 h, and the reaction was terminated by adding SDS-PAGE sample buffer and boiling the mixture.

**Recombinant human IGFBP-1 (rhlGFBP-1) proteolysis in amniotic fluid**

rhlGFBP-1 (100 ng; R&D systems, Minneapolis, MN) was incubated in 10 µL of AF with or without inflammation. The solution was incubated at 37°C for 6–12 h, and the reaction was stopped by adding reducing sample buffer and boiling the mixture. A time course of IGFBP-1 degradation in AF was evaluated by analyzing the aliquots with Western blot.

**Densitometric analysis**

Densitometric analysis of the results of Western blot (scanned images of membranes) was performed with the TINA 2.0 software program (Raytest, Staubenhardt). Ratio of proteolytic fragment to intact IGFBP-1 was calculated. The fragmented/intact IGFBP-1 ratio in AF between groups with and without inflammation were compared with the Mann-Whitney U-test. A P-value of <0.05 was considered significant.

**Results**

**Difference in the form of IGFBP-1 in AF with and without inflammation**

Results of Western blot analysis for IGFBP-1 in AF showed that IGFBP-1 was present in AF without inflam-
mation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).

The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration

Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without inflammation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).

The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration

Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without inflammation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).

The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration

Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without inflammation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).

The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration

Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without inflammation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).

The relationship between the change of IGFBP-1 and the degree of AF inflammation measured by AF MMP-8 concentration

Figure 3 shows that a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of AF MMP-8. Fragment detection decreased in AF without inflammation as an intact form of 30 kDa (Figure 1). However, the intact form of IGFBP-1 decreased and fragments were seen at 21, 17 and 12 kDa on the result of immunoblot for AF with inflammation. A total of 20 cases were analyzed, and the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation (Figure 2).
inflammation (Figure 3A, lanes 1 and 2). As AF MMP-8 concentration increased, fragments of IGFBP-1 increased and intact IGFBP-1 decreased. At higher MMP-8 concentrations, intact IGFBP-1 almost disappeared (Figure 3A, lanes 5–7).

**rhIGFBP-1 degradation in AF with inflammation**

Figure 4 shows the change of exogenous rhIGFBP-1 in AF with and without inflammation. Experiments were done on four cases of AF. MMP-8 concentrations of AF with inflammation were 415.2 and 2199.9 ng/mL, and those of control AF were <0.3 ng/mL. After 12 h of incubation, intact rhIGFBP-1 was gradually degraded in AF with inflammation and 12 kDa fragment increased. However, there was no change in the form of rhIGFBP-1 in AF without inflammation.

**Time-course of IGFBP-1 proteolysis by exogenous MMP-3, MMP-8 and MMP-9**

Figure 5 demonstrates that AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9 in a time-dependent manner. MMP-3 cleaved intact IGFBP-1 in AF into three fragments of 23, 21 and 12 kDa. MMP-9 degraded into 21, 17 and 12 kDa fragments. MMP-8 proteolyzed AF IGFBP-1 into four fragments of 21, 17, 14 and 12 kDa. However, there was no change in the form of AF IGFBP-1 in the control AF.

**Comment**

**Principal findings of this study**

1) IGFBP-1 was present as an intact form in AF without inflammation. However, a fragmented form of IGFBP-1 was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher degree of inflammation; 4) rhIGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation; and 5) *in vitro* experiments showed that an intact form of IGFBP-1 in AF was degraded by

![Figure 4](image-url)  
**Figure 4** rhIGFBP-1 proteolysis in amniotic fluid (AF) without (A) or with (B) inflammation; 100 ng of rhIGFBP-1 was incubated in 10 µL of AF at 37°C. There was no change in the form of rhIGFBP-1 in AF without inflammation (A). However, intact rhIGFBP-1 (30 kDa) was gradually degraded in AF with inflammation and 12 kDa fragment increased (B). Independent experiments were done on four cases of AF and representative cases were shown.
Figure 5  Proteolysis of amniotic fluid (AF) IGFBP-1 in the presence MMP-3 (B), MMP-9 (C) and MMP-8 (D); 2 μL of AFs were incubated with exogenous human MMP-3, MMP-8 or MMP-9 (enzyme/substrate molar ratio = 1:1) in a solution of 50 mM Tris (pH 7.5) containing 150 mM NaCl, 10 mM CaCl$_2$, and 0.05% Triton (final volume 20 μL) at 37°C for 12–24 h. AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9 in a time-dependent manner. However, there was no change in the form of AF IGFBP-1 in the control AF (A).

exogenous human MMP-3, MMP-8 and MMP-9 in a time-dependent manner.

Degradation of IGFBP-1 in AF with inflammation

IGFBP-1 originates from decidua and exists in a high concentration during pregnancy [8, 10, 12, 19]. Substantial evidence indicates that IGFBP-1 is likely to play an important role in human pregnancy [12], and in particular, it is thought to be associated with placental development [10, 17, 19, 22]. Elevated decidual concentration of IGFBP-1 is known to inhibit invasion of trophoblast [19, 29]. A recent study indicated that cleavage of IGFBP-1 by MMP-3 and MMP-9 might increase IGF bioavailability and control placental development in early pregnancy [10]. Women with preeclampsia have a higher serum IGFBP-1 concentration compared to those with normal pregnancies [4, 16, 18]. The IGFBP system is also thought to be involved in fetal growth [6, 9, 30]. However, the role of IGFBP system in intra-uterine inflammation during pregnancy has not been discussed. This study demonstrated that IGFBP-1 in AF was cleaved by MMPs produced in an inflammatory condition. Our data suggest a possible role of AF IGFBP-1 in the pathologic process of AF inflammation leading to preterm birth.

IGFBP-1 as a substrate of MMP-8

This study reveals that MMP-3, MMP-8 and MMP-9 cause proteolytic degradation of IGFBP-1 in AF. Several studies have reported that IGFBPs play a role of a substrate for MMPs [7, 10, 13, 17, 21, 22, 24, 25]. Proteolysis of IGFBPs is the mechanism by which MMPs control the bioactivity of the IGF system. IGFBP-1 has been reported as a substrate for MMP-2, MMP-3, MMP-7, MMP-9, and MMP-11 [7, 10, 21, 25]. The proteolysis of IGFBP-1 by MMP-3 and MMP-9 was also demonstrated in the present study. However, to our knowledge, this is the first study showing that MMP-8 is responsible for the proteolysis of IGFBP-1. This novel finding suggests that MMP-8 could regulate bioavailability of the IGF system.
in an inflammatory condition by means of proteolysis of IGFBP-1.

**AF IGFBP-1 fragment as a possible biomarker of preterm birth**

Our data showed that a specific proteolytic fragment of IGFBP-1 might be a novel biomarker of intra-amniotic inflammation leading to preterm birth. Indeed, a proteomics-based study has found 11 kDa proteolytic fragment of IGFBP-1 in AF and pooled maternal serum of patients with intra-amniotic infection [15]. Our study proved the mechanism for the production of fragments of IGFBP-1, which was MMPs-related proteolysis in AF with inflammation. Moreover, our data showed that not only the 11 kDa fragment but other fragments (21, 17 and 14 kDa) should be considered.

Intra-uterine inflammation/infection, as well as other pathologic mechanisms (e.g., activation of the maternal or fetal HPA axis, systemic inflammation, decidual hemorrhage, and pathologic distension of the uterus) can result in preterm birth [1]. Present data only suggest a proteolytic fragment of IGFBP-1 as a marker of AF inflammation/infection. However, proteolysis of IGFBP-1 may occur to regulate IGF system of the fetal/maternal system in the absence of intra-amniotic inflammation. Coppock et al. [10] demonstrated that decidual cells produced protease as well as IGFBP-1 in the first trimester, and cleavage of IGFBP-1 by MMP-3 and MMP-9 occurred to control placental development. Moreover, “decidual activation” is considered as a common biochemical pathway involving initiating parturition. Therefore, future research is needed to evaluate if a specific proteolytic fragment of IGFBP-1 could be a biomarker of preterm birth resulting from other mechanisms of disease.

**References**


isoforms in human extraembryonic cavities, maternal serum, and decidua suggests decidua as the primary source of IGFBP-1 in these fluids during early pregnancy. J Clin Endocrinol Metab. 1997;82:1894–8.


Received March 13, 2008. Accepted May 6, 2008.